Broadwood Capital Inc.
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Broadwood Capital Inc. reported 7 stock positions worth $1.3 billion. Its top holding was Monster Beverage (MNST) at 34.1% of the portfolio, followed by Axon Enterprise (AXON, 33.5%) and Staar Surgical (STAA, 20.6%). Compared with Q3 2024, it added to 2 and reduced 1. The biggest buy was Insight Molecular Diagnostic (IMDX, shares +27%) and the biggest sale Axon Enterprise (AXON, shares −5%).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001278387
- Portfolio Value
- $1.3B (Q4 2024)
- SEC Filing
- 0000919574-25-001263 ↗ filed Feb 14, 2025
Holdings Value
Holdings 7 stocks · $1.3B
| MNST Monster Beverage Corp. | 34.06% | 8,295,690 | $436.0M | No change |
| AXON Axon Enterprise Inc. | 33.54% | 722,421 | $429.3M | Reduce -5.0% |
| STAA Staar Surgical Co. | 20.59% | 10,848,631 | $263.5M | Add +0.7% |
| IWM iShares Russell 2000 ETF | 8.98% | 519,920 | $114.9M | No change |
| LCTX Lineage Cell Therapeutics Inc. | 1.64% | 41,666,255 | $20.9M | No change |
| IMDX Insight Molecular Diagnostic filed as ONCOCYTE CORP | 1.16% | 6,244,405 | $14.9M | Add +26.7% |
| SER Serina Therapeutics Inc. | 0.03% | 85,219 | $427K | No change |
Portfolio Sells Q3 2024 → Q4 2024
| AXON Axon Enterprise Inc. | Reduce -5.0% | 33.54% | +10.25 |
Portfolio Buys Q3 2024 → Q4 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $1.9B | MNST, STAA, AXON, IWM, IMDX |
| Q1 2026 | 6 | $1.4B | MNST, STAA, AXON, IWM, LCTX |
| Q4 2025 | 7 | $1.7B | MNST, AXON, STAA, IWM, IMDX |
| Q3 2025 | 7 | $1.7B | MNST, AXON, STAA, IWM, LCTX |
| Q2 2025 | 8 | $1.5B | AXON, MNST, STAA, IWM, LCTX |
| Q1 2025 | 8 | $1.2B | MNST, AXON, STAA, IWM, IMDX |
| Q4 2024 | 7 | $1.3B | MNST, AXON, STAA, IWM, LCTX |
| Q3 2024 | 7 | $1.3B | MNST, STAA, AXON, IWM, LCTX |
| Q2 2024 | 7 | $1.3B | STAA, MNST, AXON, IWM, LCTX |
| Q1 2024 | 7 | $1.3B | MNST, STAA, AXON, IWM, LCTX |